Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 12/20 | 0.39 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475725 | 0.85 | CHEK1 (0.45) | CHEK1MAP3K7JAK2KDRADORA1 | |
| SCHEMBL5795592 | 0.83 | ADORA1 (0.46) | CHEK1MAP3K7JAK2KDRADORA1 | |
| SCHEMBL5483335 | 0.82 | KDM4E (0.44) | CHEK1 | |
| SCHEMBL5478073 | 0.81 | CHEK1 (0.63) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5469037 | 0.77 | CHEK1 (0.66) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5469691 | 0.70 | CHEK1 (0.37) | CHEK1KDRADORA1 | |
| SCHEMBL14492323 | 0.70 | CHEK1 (0.43) | CHEK1HSP90AA1 | |
| SCHEMBL5478074 | 0.70 | ADORA1 (0.38) | KDRADORA1 | |
| SCHEMBL5469935 | 0.68 | CHEK1 (0.54) | CHEK1MAP3K7JAK2KDR | |
| SCHEMBL5470898 | 0.66 | CHEK1 (0.48) | CHEK1MAP3K7JAK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | claimed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | CHEK1 13/4885MAP3K7 923/4885JAK2 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.